Non-erythropoietic tissue-protective peptides derived from erythropoietin: WO2009094172

Bibliography

• Koury MJ, Bondurant MC. The molecular mechanism of erythropoietin action. Eur J Biochem 1992;210:649-63
   PubMedGoogle Scholar
• Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003;228:1-14
   PubMed Web of Science ®Google Scholar
• Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006;70:246-50
   PubMed Web of Science ®Google Scholar
• Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008;141:14-31
   PubMed Web of Science ®Google Scholar
• Maiese K, Chong ZZ, Shang YC. Raves and risks for erythropoietin. Cytokine Growth Factor Rev 2008;19:145-55
   PubMed Web of Science ®Google Scholar
• Livnah O, Stura EA, Johnson DL, Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1996;273:464-71
   PubMed Web of Science ®Google Scholar
• Calò LA, Davis PA, Piccoli A, A role for heme oxygenase-1 in the antioxidant and antiapoptotic effects of erythropoietin: the start of a good news/bad news story? Nephron Physiol 2006;103:107-11
   Google Scholar
• Katavetin P, Tungsanga K, Eiam-Ong S, Antioxidative effects of erythropoietin. Kidney Int Suppl 2007;107:S10-15
   PubMed Web of Science ®Google Scholar
• Maiese K, Hou J, Chong ZZ, Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology. ScientificWorldJournal 2009;9:1072-104
   PubMedGoogle Scholar
• Bennett CL, Silver SM, Djulbegovic B, Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Weissenborn K, Prange H, Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40:647-56
   PubMed Web of Science ®Google Scholar
• Hardee ME, Arcasoy MO, Blackwell KL, Erythropoietin biology in cancer. Clin Cancer Res 2006;12:332-9
   PubMed Web of Science ®Google Scholar
• McKoy JM, Stonecash RE, Cournoyer D, Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008;48:1754-62
   PubMed Web of Science ®Google Scholar
• Jelkmann W. ‘O’, erythropoietin carbamoylation versus carbamylation. Nephrol Dial Transplant 2008;23:3033
   PubMedGoogle Scholar
• Leist M, Ghezzi P, Grasso G, Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-42
   PubMed Web of Science ®Google Scholar
• Kenneth S Warren Institute Inc, Lundbeck and Co AS. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs. WO2004003176; 2004
   Google Scholar
• Kenneth S Warren Institute Inc. Long acting tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues anmd organs. WO2005084364; 2005
   Google Scholar
• Kenneth S Warren Institute Inc. Novel carbamylated EPO and method for its production. WO2006014466; 2006
   Google Scholar
• Murphy JM, Young IG. IL-3, IL-5, and GM-CSF signaling: crystal structure of the human beta-common receptor. Vitam Horm 2006;74:1-30
   PubMed Web of Science ®Google Scholar
• Brines M, Grasso G, Fiordaliso F, Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101:149007-14912
   Google Scholar
• Kenneth S Warren Institute Inc. Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof. WO2004096148; 2004
   Google Scholar
• Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008;264:405-32
   PubMed Web of Science ®Google Scholar
• University of California. Prosaposin and cytokine-derived peptides US5700909; 1997
   Google Scholar
• Campana WM, Misasi R, O'Brien JS. Identification of a neurotrophic sequence in erythropoietin. Int J Mol Med. 1998;1:235-41
   PubMed Web of Science ®Google Scholar
• Charite Universitaetsmedizin. Erythropoietin variants. WO2006120030; 2006
   Google Scholar
• Brines M, Patel NS, Villa P, Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008;105:10925-30
   PubMed Web of Science ®Google Scholar
• Warren Pharmaceuticals, Inc. Tissue protective peptides and uses thereof. WO2007019545; 2007
   Google Scholar
• Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage. WO2009094172; 2009
   Google Scholar
• Erbayraktar Z, Erbayraktar S, Yilmaz O, Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing. Mol Med 2009;15:235-41
   PubMed Web of Science ®Google Scholar
• Dumont F, Le Roux A, Bischoff P. Radiation countermeasure agents: an update. Expert Opin Ther Patents 2010;20:73-101
   PubMed Web of Science ®Google Scholar
• Erbayraktar S, de Lanerolle N, de Lotbinière A, Carbamylated erythropoietin reduces radiosurgically-induced brain injury. Mol Med 2006;12:74-80
   PubMed Web of Science ®Google Scholar
• Affymax, Inc. Peptides that bind to the erythropoietin receptor. WO2004101611; 2004
   Google Scholar
• Affymax, Inc. Erythropoietin receptor peptide formulations and uses. WO2009025958; 2009
   Google Scholar
• Woodburn KW, Wilson SD, Fong KL, Chronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents. Basic Clin Pharmacol Toxicol 2009;104:155-63
   PubMed Web of Science ®Google Scholar
• Arcasoy MO. Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives. Clin Cancer Res 2008;14:4685-90
   PubMed Web of Science ®Google Scholar
• Alepor GMBH & Co KG. Novel tissue protective erythropoietin receptor (NEPOR) and methods of use. WO2009068677; 2009
   Google Scholar
• Arvanitis D, Davy A. Eph/ephrin signaling: networks. Genes Dev 2008;22:416-29
   PubMed Web of Science ®Google Scholar
• Hansen G, Hercus TR, McClure BJ, The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell 2008;134:496-507
   PubMed Web of Science ®Google Scholar
• Dey R, Ji K, Liu Z, A cytokine-cytokine interaction in the assembly of higher-order structure and activation of the interleukine-3:receptor complex. PLoS one 2009;4:e5188
   Google Scholar
• Mahmood A, Lu D, Qu C, Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin. J Neurosurg 2007;107:392-7
   PubMed Web of Science ®Google Scholar
• King VR, Averill SA, Hewazy D, Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. Eur J Neurosci 2007;26:90-100
   PubMed Web of Science ®Google Scholar
• Bianchi R, Brines M, Lauria G, Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res 2006;12:2607-12
   PubMed Web of Science ®Google Scholar
• Mennini T, De Paola M, Bigini P, Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med 2006;12:153-60
   PubMed Web of Science ®Google Scholar
• Savino C, Pedotti R, Baggi F, Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol 2006;172:27-37
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang ZG, Rhodes K, Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol 2007;151:1377-84
   PubMed Web of Science ®Google Scholar
• Villa P, van Beek J, Larsen AK, Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab 2007;27:552-63
   PubMed Web of Science ®Google Scholar
• Lapchak PA, Kirkeby A, Zivin JA, Therapeutic window for nonerythropoietic carbamylated-erythropoietin to improve motor function following multiple infarct ischemic strokes in New Zealand white rabbits. Brain Res 2008;1238:208-14
   PubMed Web of Science ®Google Scholar
• Fiordaliso F, Chimenti S, Staszewsky L, A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 2005;102:2046-51
   PubMed Web of Science ®Google Scholar
• Moon C, Krawczyk M, Paik D, Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 2006;316:999-1005
   PubMed Web of Science ®Google Scholar
• Xu X, Cao Z, Cao B, Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Surgery 2009;146:506-14
   PubMedGoogle Scholar
• Imamura R, Isaka Y, Ichimaru N, Carbamylated erythropoietin protects the kidneys from ischemia-reperfusion injury without stimulating erythropoiesis. Biochem Biophys Res Commun 2007;353:786-92
   PubMedGoogle Scholar
• Imamura R, Okumi M, Isaka Y, Carbamylated erythropoietin improves angiogenesis and protects the kidneys from ischemia-reperfusion injury. Cell Transplant 2008;17:135-41
   PubMedGoogle Scholar
• Kitamura H, Isaka Y, Takabatake Y, Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model. Nephrol Dial Transplant 2008;35:1521-8
   Google Scholar
• Siren AL, Fasshauer T, Bartels C, Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 2009;6:108-27
   PubMed Web of Science ®Google Scholar
• Xiong Y, Mahmood A, Chopp M. Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs 2009;14:67-84
   PubMed Web of Science ®Google Scholar
• Baptiste DC, Fehlings MG. Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs 2008;13:63-80
   PubMed Web of Science ®Google Scholar
• Matis GK, Birbilis TA. Erythropoietin in spinal cord injury. Eur Spine J 2009;18:314-23
   PubMed Web of Science ®Google Scholar
• Mahmood D, Singh BK, Akhtar M. Diabetic neuropathy: therapies on the horizon. J Pharm Pharmacol 2009;61:1137-45
   PubMed Web of Science ®Google Scholar
• Chung H, Lee H, Lamoke F, Neuroprotective role of erythropoietin by antiapoptosis in the retina. J Neurosci Res 2009;87:2365-74
   PubMed Web of Science ®Google Scholar
• Rosamond W, Flegal K, Furie K, Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-146
   PubMed Web of Science ®Google Scholar
• Vogiatzi G, Briasoulis A, Tousoulis D, Is there a role for erythropoietin in cardiovascular disease? Expert Opin Biol Ther 2009. In press
   Google Scholar
• Timmer SA, De Boer K, Knaapen P, The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis? J Card Fail 2009;15:353-61
   PubMed Web of Science ®Google Scholar
• Bahlmann FH, Fliser D. Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens 2009;18:15-20
   PubMed Web of Science ®Google Scholar
• Kosieradzki M, Rowiński W. Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant Proc 2008;40:3279-88
   PubMed Web of Science ®Google Scholar
• Velnar T, Bailey T, Smrkolj V. The wound healing process: an overview of the cellular and molecular mechanisms. J Int Med Res 2009;37:1528-42
   PubMed Web of Science ®Google Scholar
• Fliedner TM, Chao NJ, Bader JL, Stem cells, multiorgan failure in radiation emergency medical preparedness: a US /European Consultation Workshop. Stem Cells 2009;27:1205-11
   PubMed Web of Science ®Google Scholar